HemorrhoidsNCT00693459
Study of a New Circular Anal Dilator
A study testing Circular Anal Dilator for Transanal Hemorrhoidectomy in people with Hemorrhoids, run by University Hospitals Cleveland Medical Center at 1 site in United States.
Trial summary
The purpose of this research study is to test the effectiveness of a new anoscope used while performing a traditional hemorrhoidectomy. Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Hemorrhoids
- What is being tested?
- Circular Anal Dilator for Transanal Hemorrhoidectomy
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 20 participants
- Where
- 1 siteUnited States
- Study dates
- May 2008to Jun 2011
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Subjects with internal or external symptomatic hemorrhoids.
- Subjects who have failed, or are not suitable for office management of their hemorrhoids.
- Subjects who are 18 years of age and older
- Subjects of either gender
- Subjects, who are willing and able to adhere to protocol requirements, agree to participate in the study program and provide written and informed consent
Who cannot join
- Subjects who have had previous hemorrhoid surgery.
- Subjects with internal hemorrhoids that may be suitable for office management.
- Subjects with incontinence.
- Subjects with evidence of acute sepsis or the presence of a fistula.
- Subjects with a medical condition that may interfere with the evaluation of safety or effectiveness of the study device.
- Subjects who have another condition that in the opinion of the investigator precludes further participation in the study.
- Subjects with an anal stricture.
Trial locations and contacts
1 site in 1 country.
United States1 site
University Hospitals of Cleveland Case Medical Center
Cleveland, Ohio, 44106
About this study
Official title: Feasibility Study of a New Circular Anal Dilator for Transanal Hemorrhoidectomy
The purpose of this research study is to test the effectiveness of a new anoscope used while performing a traditional hemorrhoidectomy.
Read the detailed description
Historically, surgical hemorrhoidectomy has been effective at eliminating hemorrhoids but is associated with high complication rates and post-operative disability. The problems that are most common immediately after hemorrhoidectomy are severe pain, urinary retention, bleeding and fecal impaction. The most dreaded long term complications are anal stricture and fecal incontinence.
Stricture or narrowing of the anal canal after hemorrhoidectomy is the direct result of excising too much anoderm and mucosa. Even in circumferential prolapsed hemorrhoids, a standard three quadrant hemorrhoidectomy is all that is necessary. Mild anal stricture can be treated with a Hegar dilator but severe stricture requires a lateral internal sphincterotomy with or without a skin advancement flap. These operations are morbid and results are generally poor.
Anal sensation is partially impaired leading to some degree of incontinence of 50% of patients after hemorrhoidectomy. Persistent incontinence results from being over aggressive during the hemorrhoidectomy and excising muscle with the hemorrhoid during dissection.
The majority of these long term complications are solely dependent on surgical technique. The majority of hemorrhoidectomies performed today are still performed by non-specialty surgeons. They rely on various instruments during the surgery to perform the operation in the anal canal with adequate exposure but the most important instrument is the anoscope.
A variety of anoscopes are currently available, but the standard anoscope used for hemorrhoidectomy is the Hill-Ferguson. The Hill-Ferguson is a crescent shaped instrument that provides adequate exposure in the anal canal and allows the surgeon to perform a Ferguson hemorrhoidectomy, the standard of care for hemorrhoidectomy in this country. During this procedure an elliptical excision is begun at the perianal skin to include both external and internal hemorrhoids and is ended at the anorectal ring. A full thickness of mucosa and submucosa is excised and the surgeon should dissect superficial to the internal sphincter muscle. The strip of this excision should be no wider than 1.5 cm but currently nothing prevents the surgeon from exceeding this limitation or from taking muscle with the excision. The widely accepted Hill-Ferguson Anoscopes provide vast exposure but do not set any boundaries for the surgeon when performing this operation.
Over the last several decades few modifications have been introduced to alter the contour of the anoscope in an attempt to reduce the complications of post-operative stricture and incontinence. Furthermore, the current anoscopes lack the ability to outline a precise excision path for the infrequent anorectal surgeon or for the non-specialist in the community.
Recently, Ethicon surgical has developed an anoscope that outlines the precise path for hemorrhoid excision without the possibility of excision greater than 1.5 cm of anoderm with each excision. This instrument allows the standard of care Ferguson hemorrhoidectomy to be performed and does not alter the steps of the operation. The presumed advantages are the ability of the instrument to guide an accurate dissection and also to decrease the overall time it takes to perform hemorrhoidectomy. It has been tested in several porcine models. Operative times, tissue excised, and evaluation of the suture line were addressed during these trials and there were no instances of bleeding or excessive tissue excision.
The study design will be a prospective feasibility trial. Patients who are scheduled for operative excisional hemorrhoidectomy will undergo their planned procedure according to the standard of care which is a Ferguson hemorrhoidectomy. The only new variable introduced will be the application of a new anoscope to facilitate the dissection. Other than the new anoscope all pre-operative, intra-operative, and post-operative guidelines consistent with the current standards will be followed. The primary goal is to confirm that the new anoscope permits standard hemorrhoidectomy, and to obtain phase I data confirming that this novel anoscope is safe and efficacious in the performance of a Ferguson hemorrhoidectomy.
- Conditions
- Hemorrhoids
- Being tested
- Circular Anal Dilator for Transanal Hemorrhoidectomy
- Keywords
- Hemorrhoids
- Medical subject headings
- Hemorrhoids
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Circular Anal Dilator for Transanal HemorrhoidectomyDevice
Also called Chemo 2
The Circular Anal Dilator for Transanal Hemorrhoidectomy (product #CAD01) allows the standard of care Ferguson hemorrhoidectomy to be performed and does not alter the steps of the operation. The presumed advantages are the ability of the dilator to guide an accurate dissection and also to decrease the overall time it takes to perform hemorrhoidectomy.
| Study group | Role | What they receive |
|---|---|---|
| Circular anal dilator | Other | Circular anal dilator group-An anoscope has been developed that outlines the precise path for hemorrhoid excision. This instrument allows a modified Ferguson hemorrhoidectomy to be performed and does not alter the steps of the operation. Receives: Device: Circular Anal Dilator for Transanal Hemorrhoidectomy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Evaluate the safety of the new device by the number of participants with Adverse Events
This study will be monitored to ensure the identification, documentation and analysis of all adverse events in regards to safety and efficacy of the new device. All adverse events, unforeseen or otherwise will be recorded as data. Information will be reported on the 1)Visual Analog Pain scores, 2)Incontinence score, using the Wexner Oliveira score, 3) Presence of Stenosis 4) Continued bleeding or symptoms, 5) Wound Infection, 6) Bladder Retention
Measured: 1 year post-operative
Secondary outcomes (1)
Evaluate the efficacy of the new device by the number of participants with Adverse Events
This study will be monitored to ensure the identification, documentation and analysis of all adverse events in regards to safety and efficacy of the new device. All adverse events, unforeseen or otherwise will be recorded as data. Information will be reported on the 1)Visual Analog Pain scores, 2)Incontinence score, using the Wexner Oliveira score, 3) Presence of Stenosis 4) Continued bleeding or symptoms, 5) Wound Infection, 6) Bladder Retention
Measured: 1 year post operative
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Jun 2008 (estimated)
- Study startMay 2008
- Primary completionJun 2011
- Study completionJun 2011
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HemorrhoidsStudies of the same condition, open and under way.
- More trials run by University Hospitals Cleveland Medical CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Device feasibility
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 20 participants (actual)
Sponsor and investigators
- Lead sponsor
- University Hospitals Cleveland Medical Center
- Sponsor type
- University, hospital or other
- Collaborators
- Ethicon, Inc.
- Responsible party
- Sponsor
- Investigators
- Bradley Champagne, MD, Principal investigator, University Hospitals Cleveland Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00693459
- Sponsor's protocol ID
- 07-07-06
- Status last verified
- Jan 2013
- First submitted
- 27 Feb 2008
- Last updated
- 15 Aug 2022
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 15 Aug 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Feasibility Study of a New Circular Anal Dilator for Transanal Hemorrhoidectomy
- ClinicalTrials.gov ID
- NCT00693459
- Acronym / sponsor ID
- 07-07-06
- Conditions
- Hemorrhoids
- Keywords
- Hemorrhoids
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 20 participants (actual)
- Lead sponsor
- University Hospitals Cleveland Medical CenterUniversity, hospital or other
- Collaborators
- Ethicon, Inc.
- Study start
- May 2008
- Primary completion
- Jun 2011 (actual)
- Study completion
- Jun 2011 (actual)
- First posted
- 9 Jun 2008 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this research study is to test the effectiveness of a new anoscope used while performing a traditional hemorrhoidectomy.
Detailed description
Historically, surgical hemorrhoidectomy has been effective at eliminating hemorrhoids but is associated with high complication rates and post-operative disability. The problems that are most common immediately after hemorrhoidectomy are severe pain, urinary retention, bleeding and fecal impaction. The most dreaded long term complications are anal stricture and fecal incontinence.
Stricture or narrowing of the anal canal after hemorrhoidectomy is the direct result of excising too much anoderm and mucosa. Even in circumferential prolapsed hemorrhoids, a standard three quadrant hemorrhoidectomy is all that is necessary. Mild anal stricture can be treated with a Hegar dilator but severe stricture requires a lateral internal sphincterotomy with or without a skin advancement flap. These operations are morbid and results are generally poor.
Anal sensation is partially impaired leading to some degree of incontinence of 50% of patients after hemorrhoidectomy. Persistent incontinence results from being over aggressive during the hemorrhoidectomy and excising muscle with the hemorrhoid during dissection.
The majority of these long term complications are solely dependent on surgical technique. The majority of hemorrhoidectomies performed today are still performed by non-specialty surgeons. They rely on various instruments during the surgery to perform the operation in the anal canal with adequate exposure but the most important instrument is the anoscope.
A variety of anoscopes are currently available, but the standard anoscope used for hemorrhoidectomy is the Hill-Ferguson. The Hill-Ferguson is a crescent shaped instrument that provides adequate exposure in the anal canal and allows the surgeon to perform a Ferguson hemorrhoidectomy, the standard of care for hemorrhoidectomy in this country. During this procedure an elliptical excision is begun at the perianal skin to include both external and internal hemorrhoids and is ended at the anorectal ring. A full thickness of mucosa and submucosa is excised and the surgeon should dissect superficial to the internal sphincter muscle. The strip of this excision should be no wider than 1.5 cm but currently nothing prevents the surgeon from exceeding this limitation or from taking muscle with the excision. The widely accepted Hill-Ferguson Anoscopes provide vast exposure but do not set any boundaries for the surgeon when performing this operation.
Over the last several decades few modifications have been introduced to alter the contour of the anoscope in an attempt to reduce the complications of post-operative stricture and incontinence. Furthermore, the current anoscopes lack the ability to outline a precise excision path for the infrequent anorectal surgeon or for the non-specialist in the community.
Recently, Ethicon surgical has developed an anoscope that outlines the precise path for hemorrhoid excision without the possibility of excision greater than 1.5 cm of anoderm with each excision. This instrument allows the standard of care Ferguson hemorrhoidectomy to be performed and does not alter the steps of the operation. The presumed advantages are the ability of the instrument to guide an accurate dissection and also to decrease the overall time it takes to perform hemorrhoidectomy. It has been tested in several porcine models. Operative times, tissue excised, and evaluation of the suture line were addressed during these trials and there were no instances of bleeding or excessive tissue excision.
The study design will be a prospective feasibility trial. Patients who are scheduled for operative excisional hemorrhoidectomy will undergo their planned procedure according to the standard of care which is a Ferguson hemorrhoidectomy. The only new variable introduced will be the application of a new anoscope to facilitate the dissection. Other than the new anoscope all pre-operative, intra-operative, and post-operative guidelines consistent with the current standards will be followed. The primary goal is to confirm that the new anoscope permits standard hemorrhoidectomy, and to obtain phase I data confirming that this novel anoscope is safe and efficacious in the performance of a Ferguson hemorrhoidectomy.
Study design
- Primary purpose
- Device feasibility
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Circular anal dilator | Other | Device: Circular Anal Dilator for Transanal HemorrhoidectomyCircular anal dilator group-An anoscope has been developed that outlines the precise path for hemorrhoid excision. This instrument allows a modified Ferguson hemorrhoidectomy to be performed and does not alter the steps of the operation. |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Subjects with internal or external symptomatic hemorrhoids.
- Subjects who have failed, or are not suitable for office management of their hemorrhoids.
- Subjects who are 18 years of age and older
- Subjects of either gender
- Subjects, who are willing and able to adhere to protocol requirements, agree to participate in the study program and provide written and informed consent
Key exclusion criteria (7 listed)
- Subjects who have had previous hemorrhoid surgery.
- Subjects with internal hemorrhoids that may be suitable for office management.
- Subjects with incontinence.
- Subjects with evidence of acute sepsis or the presence of a fistula.
- Subjects with a medical condition that may interfere with the evaluation of safety or effectiveness of the study device.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Circular Anal Dilator for Transanal HemorrhoidectomyAlso: Chemo 2The Circular Anal Dilator for Transanal Hemorrhoidectomy (product #CAD01) allows the standard of care Ferguson hemorrhoidectomy to be performed and does not alter the steps of the operation. The presumed advantages are the ability of the dilator to guide an accurate dissection and also to decrease the overall time it takes to perform hemorrhoidectomy. | Device | Circular anal dilator |
Primary outcome
Evaluate the safety of the new device by the number of participants with Adverse Events
Time frame: 1 year post-operative
This study will be monitored to ensure the identification, documentation and analysis of all adverse events in regards to safety and efficacy of the new device. All adverse events, unforeseen or otherwise will be recorded as data. Information will be reported on the 1)Visual Analog Pain scores, 2)Incontinence score, using the Wexner Oliveira score, 3) Presence of Stenosis 4) Continued bleeding or symptoms, 5) Wound Infection, 6) Bladder Retention
1 secondary outcome
Evaluate the efficacy of the new device by the number of participants with Adverse Events
Time frame: 1 year post operative
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Aug 2022.
Related trials for Hemorrhoids
Not yet recruiting
Auricular Indwelling Needles Added to Diosmin/Hesperidin for Grade I-II Internal Hemorrhoids With Heat-Toxin Syndrome
Internal Haemorrhoids
Enrolling by invitation
Ultrasound-Guided Versus Landmark-Guided Pudendal Block for Post-Hemorrhoidectomy Pain
Hemorrhoids, Postoperative Pain
Not yet recruitingObservational study
Bleeding Reduction in Grade II-III Haemorrhoids Through Embolization Treatment
Hemorrhoid, Hemorrhoid Bleeding
Recruiting
Ligasure Versus Conventional Diathermy in Hemorrhoidectomy
Hemorrhoids
Enrolling by invitationObservational study
Case-Specific Health Care Professional Clinical Survey for Concerto Versa™ Detachable Coils
Arteriovenous Malformation, Gastrointestinal Bleed
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Bradley Champagne, MD principal investigator
University Hospitals Cleveland Medical Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Circular Anal Dilator for Transanal Hemorrhoidectomy in people with Hemorrhoids, run by University Hospitals Cleveland Medical Center at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 15 Aug 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Evaluate the safety of the new device by the number of participants with Adverse Events (time frame: 1 year post-operative). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Aug 2022.